OLIPASS CORPORATION Logo

OLIPASS CORPORATION

An R&D company developing RNA therapeutics using its proprietary OPNA platform.

244460 | KO

Overview

Corporate Details

ISIN(s):
KR7244460002
LEI:
Country:
South Korea
Address:
경기도 용인시 기흥구 동백중앙로16번길 16-4 에이스동백타워1동 20층, 용인시

Description

OLIPASS CORPORATION is a research and development company focused on creating RNA therapeutics. The company's core activities are centered on its proprietary OliPass Peptide Nucleic Acid (OPNA) platform. OPNA is a novel technology derived from Peptide Nucleic Acid (PNA) by introducing a cationic lipid moiety onto the nucleobase. This structural modification is designed to markedly improve cell permeability, a key challenge in nucleic acid-based drug delivery. The platform is optimized to induce exon skipping by specifically binding to target pre-mRNA inside the cell nucleus, enabling the discovery and development of new therapeutic candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 00:00
[기재정정]투자판단관련주요경영사항 (OliPass PNA 플랫폼 기술 기반 희귀질환 치료제 및 면역항암제 관련 치료제 …
Korean 13.2 KB
2025-07-23 00:00
불성실공시법인지정예고 (공시번복 2건)
Korean 6.6 KB
2025-07-22 00:00
기타시장안내 (개선계획서 제출)
Korean 4.1 KB
2025-07-15 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-07-09 00:00
[기재정정]주주총회소집결의 (임시주주총회)
Korean 10.7 KB
2025-07-09 00:00
[기재정정]주주명부폐쇄기간또는기준일설정
Korean 7.5 KB
2025-07-01 00:00
주식등의대량보유상황보고서(일반)
Korean 84.3 KB
2025-07-01 00:00
기타시장안내 (상장적격성 실질심사 대상 결정)
Korean 4.4 KB
2025-07-01 00:00
주권매매거래정지기간변경 (상장적격성 실질심사 대상 결정)
Korean 5.2 KB
2025-06-25 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 35.4 KB
2025-06-25 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 35.2 KB
2025-06-25 00:00
기타주요경영사항 (제3자배정 유상증자 결정 철회)
Korean 7.0 KB
2025-06-11 00:00
[기재정정]주주총회소집결의 (임시주주총회)
Korean 10.3 KB
2025-06-10 00:00
기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내)
Korean 3.2 KB
2025-05-22 00:00
대표이사변경
Korean 10.7 KB

Automate Your Workflow. Get a real-time feed of all OLIPASS CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OLIPASS CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OLIPASS CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.